Skip to content

UAE Bans Ciprofloxacin in Veterinary Products From November 1: What Every Business in the Sector Must Do Now


UAE Bans Ciprofloxacin in Veterinary Products From November 1 What Every Business in the Sector Must Do Now - Hawkridge Corp

The Emirates Drug Establishment has announced a significant regulatory decision that affects every business involved in the import, manufacture, supply, or use of veterinary antibiotics in the UAE. Effective November 1, 2026 just twelve days from today the use of ciprofloxacin in veterinary medicinal products and raw materials is banned across the entire UAE market. The decision is part of the UAE’s National Action Plan on Antimicrobial Resistance and reflects a growing global consensus that restricting critically important antibiotics to human medicine is essential for protecting public health. If your business handles veterinary products containing ciprofloxacin, you have less than two weeks to act.

What the Emirates Drug Establishment Has Announced

The Emirates Drug Establishment (EDE) the UAE’s federal authority for pharmaceutical product regulation announced that ciprofloxacin is prohibited for veterinary purposes from 1 November 2026. The decision covers veterinary medicinal products containing ciprofloxacin and raw materials used in the manufacture of such products.

The ban affects nine registered veterinary products in the UAE eight of which are imported products and one of which is a locally registered product. All manufacturers, importers, and suppliers of these products have been formally notified by the EDE and have been instructed to:

  • Stop manufacturing, importing, and supplying veterinary ciprofloxacin products with immediate effect
  • Withdraw all existing quantities of the banned products from the local market before November 1, 2026
  • Re-export remaining stock to its country of origin or dispose of it under approved disposal procedures regulated by the EDE

The EDE is also developing and will implement a compliance monitoring plan to verify that all relevant establishments complete the required procedures within the specified timeframe. Non-compliant businesses will be subject to the enforcement powers available to the EDE under Federal Decree-Law No. 10 of 2025 on Medical Products and Federal Decree-Law No. 21 of 2025 on Veterinary Medical Products.

What Is Ciprofloxacin and Why Is It Being Banned for Veterinary Use?

Ciprofloxacin is an antibacterial agent which falls under the category of fluoroquinolone and serves as a broad spectrum antibiotic drug. It is used to cure various bacterial infections including UTI, RTIs, skin and soft tissue infections, and gastro-intestinal infections in humans. The significance of this drug is based on the fact that it is effective against both gram-positive and gram-negative bacteria.

CIA Classification: Importance of Fluoroquinolones for Human Medicine

Ciprofloxacin is one of the many fluoroquinolones included in the list of Critically Important Antimicrobials (CIAs) in human medicine according to WHO. This designation is reserved for antibiotics that serve as the last or only remaining effective treatment for certain serious bacterial infections and where resistance would therefore have catastrophic consequences for patient outcomes. The CIA classification carries a strong international recommendation that use of these antibiotics in animals should be minimised or eliminated to protect their clinical value in human healthcare.

The EDE’s decision specifically references the CIA classification as a key factor in the ciprofloxacin ban. Fluoroquinolone use in veterinary settings including livestock, poultry, and companion animals has been identified through international surveillance data as a driver of resistance that crosses the animal-human barrier. Bacteria that develop resistance to ciprofloxacin in an animal can transfer that resistance to humans through direct contact, through the food chain, or through environmental pathways including water and soil.

The Human Health Consequence of Veterinary Overuse

When ciprofloxacin is used inappropriately in animals for preventive purposes, for growth promotion, or for infections where it is not clinically necessary, bacteria in those animals can adapt and develop resistance mechanisms. Once resistant bacteria are present in an animal population, they can spread to humans who handle animals, consume animal products, or come into contact with animal environments. The result is a reduced ability to treat serious bacterial infections in humans with one of medicine’s most relied-upon antibiotic classes. Dr Ruqaya Aqeel Al Bastaki, Acting Executive Director of the Medical Products Regulation Sector at the EDE, confirmed that scientific evidence was central to the timing and scope of this decision.

What Exactly Does the Ciprofloxacin Ban Cover?

The scope of the ban is broad and covers two categories of product:

  • Veterinary medicinal products containing ciprofloxacin: Any registered veterinary medicine with ciprofloxacin as an active ingredient whether a solution for injection, an oral suspension, ear drops, or any other veterinary dosage form. Nine specific products are directly named in the EDE decision
  • Raw materials containing ciprofloxacin: Active pharmaceutical ingredient (API) quantities of ciprofloxacin held for the manufacture of veterinary medicines in the UAE are also covered by the ban. Manufacturers holding ciprofloxacin API for veterinary compounding or production must withdraw these materials in line with the same November 1 deadline

The ban does not affect ciprofloxacin in human pharmaceutical products, which continue to be available through licensed channels for the treatment of human infections. The restriction is specific to the veterinary pathway.

Who Is Directly Affected by This Decision?

Importers and Distributors of Veterinary Products

Any company that imports veterinary products containing ciprofloxacin into the UAE or that distributes such products through the UAE supply chain must stop these activities immediately and withdraw existing stock before November 1. Import permits for ciprofloxacin veterinary products will not be issued by the EDE from this date. Stock already in transit should be re-routed if possible; stock already in the country must be withdrawn from the market and either re-exported or disposed of under EDE-approved procedures.

Veterinary Clinics, Farms, and Animal Facilities

Veterinary practices, livestock farms, poultry operations, equine facilities, and companion animal clinics that currently hold ciprofloxacin veterinary products in their inventories must cease use and return or dispose of stock in line with the EDE’s withdrawal requirements. Any facility that continues to administer ciprofloxacin to animals after November 1 will be in direct violation of the ban.

Compounding Pharmacies Serving the Veterinary Sector

Compounding pharmacies that prepare ciprofloxacin-containing formulations for animal use must cease compounding activity for veterinary applications immediately. Raw material stocks of ciprofloxacin API designated for veterinary compounding must be withdrawn from the veterinary use chain. As with other aspects of veterinary pharmaceutical regulation, EDE oversight applies to compounding activities and the 2026 enforcement posture the EDE has demonstrated across the pharmaceutical and veterinary sectors leaves no doubt that compliance will be actively monitored.

The UAE’s Broader Antimicrobial Resistance Strategy

The prohibition of ciprofloxacin is not a stand-alone measure. It is another step in the sequence of regulatory actions undertaken by the UAE within the framework of its National Action Plan on Antimicrobial Resistance (NAP-AMR) for the period 2025-2031, in which the UAE pledges to conform to international practices in antibiotic stewardship and limitation of access to critically important antibiotics in veterinary medicine.

The Precedent: Colistin Banned in 2024

A precedent for such targeted ban was set by the UAE government through its Cabinet Decision No. 6 of 2024 that prohibited the use of colistin (Polymyxin E) in the veterinary field. Colistin had been widely used in animal farming as a growth promoter and was identified as a last-resort antibiotic for treating certain drug-resistant infections in humans. The UAE moved ahead of many countries globally in implementing this restriction, and the ciprofloxacin ban follows the same framework and rationale.

The pattern is clear. The UAE is systematically working through the WHO’s CIA list and restricting veterinary access to antibiotics in the highest-priority categories. Businesses operating in the UAE veterinary products sector should treat the ciprofloxacin ban not as a one-off event but as part of a continuing programme of antibiotic restriction that will likely extend to further fluoroquinolone compounds and other CIA classes in the years ahead.

In accordance with the UAE legal provisions, the legal framework for banning antibiotic use in animal care is laid down in the Executive Regulations of Federal Law No. 9 of 2017 regarding Veterinary Preparations where it is banned to use antibiotics in animals for preventive or immunizing purposes and growth promotion of animals under Article 15, Clause 3. However, Federal Decree-Law No. 21 of 2025 has made a new legal framework in this regard. The ciprofloxacin ban is issued under this strengthened legal architecture with the enforcement powers of the EDE fully available to ensure compliance.

What Every Affected Business Must Do Before November 1, 2026

Given the time period, businesses must move quickly across five immediate actions:

  • Audit your inventory now: Identify every product in your current stock that contains ciprofloxacin as an active ingredient, including both finished veterinary products and raw materials
  • Halt all incoming orders and imports: Notify your suppliers immediately to stop any in-transit shipments of ciprofloxacin veterinary products destined for the UAE
  • Initiate market withdrawal: Begin withdrawing ciprofloxacin products from all distribution points, clinics, and retail channels where they are held. Document each withdrawal step for the EDE’s compliance monitoring programme
  • Arrange re-export or approved disposal: Remaining stock that cannot be sold before the ban takes effect must either be re-exported to the country of origin or disposed of under EDE-approved pharmaceutical disposal procedures. Do not retain or store banned products after November 1
  • Notify your supply chain: Ensure all downstream customers veterinary clinics, farms, and stockists are informed of the ban, the withdrawal requirement, and the November 1 deadline

How Hawkridge Corp Helps Veterinary Product Businesses Navigate UAE Regulatory Changes

The regulatory environment in the UAE for veterinary products is among the fastest changing in the region due to the enactment of Federal Decree-Law No. 21 of 2025 as well as implementation by EDE of the enforcement of regulations in all categories of veterinary products. We can help your company comprehend how the changes in regulation affect your portfolio of products and operations at Hawkridge Corp.

If you are one of those companies affected by the ban on ciprofloxacin, our services include assistance in regulatory compliance documentation, withdrawal process coordination with EDE, disposition or re-exporting logistics coordination via the regulatory process, and preparations for an audit prior to EDE compliance monitoring activities. For businesses with broader veterinary product portfolios, we provide an ongoing advisory service that tracks UAE regulatory developments including the NAP-AMR pipeline and prepares clients for changes before enforcement actions are announced.

If you hold veterinary products that may be subject to current or future UAE antibiotic restrictions, contact Hawkridge Corp today for a portfolio compliance review.

Final Thoughts

The UAE’s decision to ban ciprofloxacin for veterinary use from November 1, 2026, is a firm and scientifically grounded step in the country’s commitment to combating antimicrobial resistance. By restricting a critically important antibiotic to human medicine only, the EDE is protecting the clinical value of fluoroquinolones for generations of patients who will depend on them to treat serious bacterial infections. For the businesses affected importers, distributors, compounding pharmacies, and veterinary facility operators the immediate priority is compliance: withdrawing products from the market, halting imports, and completing disposal or re-export before the deadline. With twelve days remaining, there is no time for delay. The broader lesson is equally clear: the UAE’s NAP-AMR 2025-2031 will continue to reshape the veterinary antibiotic landscape, and businesses that build proactive regulatory awareness into their operations now will be far better positioned for the changes still to come.